Market Research Report
US CNS Disorders Drug Pipeline Insight 2014
|Published by||PNS Pharma||Product code||311224|
|Published||Content info||1700 Pages
Delivery time: 1-2 business days
|US CNS Disorders Drug Pipeline Insight 2014|
|Published: August 1, 2014||Content info: 1700 Pages||
The Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry. The numbers of CNS disorders have increased at an alarming rate, while the available therapies were unable to meet the market requirements. There has been steady to rapid growth in the market for CNS disorder, especially over the past two decades. The market for CNS therapies is one of the largest therapeutic categories and also one of the fastest growing. US account for more than 55% of the global CNS Disorders drugs market.
Within the CNS market, the biggest therapeutic area is the market for anti-psychotics, followed by anti-depressive and mood stab markets. Anti-epileptic and anti-Alzheimer's markets come next while other classes of drugs have a marginal share. Antipsychotics have a market share of nearly 30% while antidepressants corner about 25% of the market. Anti convulsants have about 17% of the market share while drugs used in Alzheimer's Disease form about 9% of the market, with ADHD and narcolepsy drugs medications have about 7% market share. The other classes of drugs have market shares of less than 5% each.
New technology including advancements in stem cell therapy and of nanotechnology is expected to drive the growth of the CNS market. Nanotechnology in the form of the nanomaterials for wound care, drug delivery and immunomodulation is specifically seen as a positive influence on CNS therapy that is expected to open growth opportunities. While each of these therapeutic subcategories are served by established treatments there are certain markets segments with significant unmet medical needs still remain, indicating potential in these areas. There are newer treatment methodologies under development such as that using stem cell therapy and of nanotechnology that seek to address these opportunities.
The rapid advances in the R&D segment, many novel drugs are currently available for the treatment of CNS disorders. Industry related to CNS drug delivery system has also got a boost due to rapid advancement of CNS disorders market. Given the magnitude of number of patients and demand for better drugs is going to push pharmaceutical companies for significant investments. Changing life-style is one the main contributor of CNS disorders in US. Increased longevity and ageing population along with launch of novel drugs will drive the growth of CNS disease market in future.
"US CNS Disorders Drug Pipeline Insight 2014" Report Highlight: